Dr. Don A. Bukstein joins Strategic Pulmonary Advisors

Strategic Pharmaceutical Advisors (SRxA) a leading U.S. healthcare strategic marketing consulting and education firm, proudly announces the addition of Don A. Bukstein, MD, as Vice President of Strategic Pulmonary Advisors (SPA), a SRxA affiliated company.

Washington, DC (PRWEB) August 21, 2008 -- Strategic Pharmaceutical Advisors (SRxA) a leading U.S. healthcare strategic marketing consulting and education firm, proudly announces the addition of Don A. Bukstein, MD, as Vice President of Strategic Pulmonary Advisors (SPA), a SRxA affiliated company.

Dr. Bukstein is a board-certified Allergist/Immunologist, Pediatric Pulmonologist, and Director of Allergy and Asthma Research at Dean Health System, Inc. in Madison, WI. An Assistant Clinical Professor in the Department of Pediatrics and Family Practice at the University of Wisconsin-Madison, he also holds staff appointments at St. Mary's Hospital Medical Center, Meriter Hospital, and the University of Wisconsin Hospital.
                    
He received his medical degree cum laude from the University of Missouri-Columbia and completed an internship and residency in Pediatrics at Children's Medical Center of Dallas, University of Texas Southwestern Medical School, and fellowships in Allergy and Immunology at National Jewish Hospital and in Pediatric Pulmonary Medicine at the University of Colorado Medical Center. He is a fellow of the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the American Thoracic Society.

Dr. Bukstein is nationally recognized as an expert in the use of Clinical Outcomes in managed care, and as an expert on physician learning and use of medical education to affect positive patient outcomes.

He has been a principal investigator in more than 50 clinical trials focusing on allergic disease, apnea, asthma, sinusitis, and outcomes research. He has published numerous articles in peer-reviewed journals including The American Journal of Managed Care, Allergy, Pediatrics, Journal of Clinical Outcomes Management, and lectures extensively to national and international audiences on topics relating to allergic disease, asthma, and quality of life/health outcomes.

Strategic Pulmonary Advisors is a network of experts in pulmonary medicine, operating under the leadership of Peter Dicpinigaitis, MD, and Bradley Chipps, MD. Recognizing the latest addition to the pulmonary team, Dr. Chipps commented, "It is an honor to work with Don. His expertise will help us provide our clients with the very highest echelon of experience and knowledge across the spectrum of disease management in respiratory disease." SRxA operates on a unique business model that utilizes clinical teams of national and international experts who partner with experts in industry and communications to provide the latest information and education in allergy, asthma, immunology, pulmonary diseases, and otolaryngology.
                                                                                    
"Since its inception, SRxA has successfully assisted pharmaceutical and medical device companies with innovative educational, clinical, regulatory, and marketing support programs with the utmost degree of scientific integrity. Dr. Bukstein's addition to our team further strengthens our services and our ability to address the needs of our clients worldwide," said Christos Efessiou, SRxA's Chief Executive Officer. In addition to Strategic Pulmonary Advisors, other clinically focused SRxA affiliates include Strategic Allergy Advisors (SAA), Strategic Ear, Nose and Throat Advisors (SENTA) and Strategic Respiratory Advisors - Europe. The company plans to introduce new affiliates in other key specialties in the near future. SRxA is headquartered in Washington, DC with offices in London and Hong Kong.

###